Indicated for treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital factor VII (FVII) deficiency, Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, and in adults with acquired hemophilia.
Congenital Factor VII deficiency
Taylor has CFVIId.
Congenital Factor VII deficiency
NovoSeven® RT can manage bleeding symptoms in hospitals and at home, offering patients with congenital FVII deficiency (CFVIId) bleed control and management.1,2
NovoSeven® RT (coagulation Factor VIIa, recombinant) does not just address symptoms—it controls bleeds at the source
Effective management of FVIId may require more than supportive care, as it can pose risk of severe, ongoing, and potentially life-threatening bleeding episodes. NovoSeven® RT is the only FDA-approved therapy for treatment of bleeding episodes and perioperative management for adults and children with FVIId, working directly at the bleed site for bleed control, even during severe episodes.1
at stopping nonsurgical and surgical bleeds in people with CFVIId1,a
aData from the published literature and internal sources for patients with FVII deficiency (N=70) treated with NovoSeven® RT for 124 bleeding episodes, surgeries, or prophylaxis regimens. Dosing ranged from 6 mcg/kg to 98 mcg/kg administered every 2 hours to 12 hours (except for prophylaxis [doses administered from 2 times per day up to 2 times per week]). Patients were treated with an average of 1 to 10 doses. Treatment was effective if bleeding stopped or the physician rated the treatment as effective. Efficacy percentage represents the combined total of 90% in trial patients, 98% in published patients, and 90% in registry patients.1
CFVIId=congenital factor VII deficiency; FVIId=factor VII deficiency.
Established safety profile
Thrombotic events in 0.8% of bleeding episodes in patients with FVIId based on clinical trial data, patient registry data, and other safety data1
Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance.1
NovoSeven® RT provides effective bleed control for your patients with FVIId1
Patients with FVIId may experience prolonged and uncontrollable bleeding episodes that require immediate action, and delays in factor administration can affect bleed resolution.3,4
Mechanism of Action (MOA)1
NovoSeven® RT replaces low or deficient FVII and binds to tissue factor to activate platelets and clotting factors directly at the bleed site, stopping bleeding
Usage in FVIId1
FDA approved for treatment of bleeding episodes and perioperative management in adults and children with congenital Factor VII deficiency
Route of administration1
Intravenous
Not intended to be a comparison of efficacy or safety.
MOA: Slows down the mechanisms related to the breakdown of clots
Usage in FVIId: Can be useful for: bleeding after surgeries, certain bleeding disorders, pregnancy complications, liver disease, and some cancers
Route of administration: Oral or intravenous
MOA: Slows down the mechanisms related to the breakdown of clots
Usage in FVIId: Reduces heavy menstrual bleeding or is used short-term for people with hemophilia to control bleeding during tooth extractions
Route of administration: Oral or intravenous
MOA: Provides multiple clotting factors to restore hemostasis
Usage in FVIId: FDA approved for those: taking blood thinners, who have a major bleeding episode, who need urgent surgery
Route of administration: Intravenous
MOA: Replaces missing clotting factors to help stop bleeding
Usage in FVIId: For bleeding and surgeries, when blood test shows clotting factor problems, specific blood disorders without alternative treatments, and brain bleeds
Route of administration: Intravenous
MOA: Can thin the uterine lining so menstrual bleeding may be lighter
Usage in FVIId: Reducing menstrual bleeding, regulating menstrual cycles, and preventing pregnancy
Route of administration: Oral, intrauterine device (IUD), arm implant, and hormone injection
MOA: Slows blood flow, reduces inflammation, and eases pain
Usage in FVIId: Used to help ease pain and decrease swelling associated with joint bleeds in people with bleeding disorders
Route of administration: Topical
MOA: Applies pressure to help stop nasal bleeding
Usage in FVIId: May help to treat nosebleeds
Route of administration: Nasal
MOA: Seals bleeding vessels through heat application
Usage in FVIId: May help to treat nosebleeds and removal of abnormal or damaged tissue
Route of administration: Nasal
MOA: Constricts nasal blood vessels to slow bleeding
Usage in FVIId: May help to treat nosebleeds
Route of administration: Nasal
NovoSeven® RT is manufactured with safety in mind
NovoSeven® RT is made without human serum or human proteins. Recombinant manufacturing minimizes the possibility of viral contamination.1,21
Find the dose for your patients with FVIIdb
bFor US health care professionals only.
Discover educational materials
Treating FVIId brochure: a resource for you and your patients
Important Safety Information for NovoSeven® RT
WARNING: THROMBOSIS
- Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
- Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
- Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis
Warnings and Precautions
- Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
- Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events
- Hypersensitivity reactions, including anaphylaxis, can occur with NovoSeven® RT. Patients with a known hypersensitivity to mouse, hamster, or bovine proteins may be at a higher risk of hypersensitivity reactions. Discontinue infusion and administer appropriate treatment when hypersensitivity reactions occur
- Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed
- Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct correlation to achieving hemostasis
Adverse Reactions
- The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions following the administration of NovoSeven® RT in clinical trials occurred in 4% of patients with acquired hemophilia and 0.2% of bleeding episodes in patients with congenital hemophilia
Drug Interactions
- Thrombosis may occur if NovoSeven® RT is administered concomitantly with Coagulation Factor XIII
Please click here for NovoSeven® RT Prescribing Information, including Boxed Warning.
Indications and Usage
NovoSeven® RT (coagulation Factor VIIa, recombinant) is a coagulation factor indicated for:
- Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
- Treatment of bleeding episodes and perioperative management in adults with acquired hemophilia
Important Safety Information for NovoSeven® RT
WARNING: THROMBOSIS
- Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
- Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
- Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis
Important Safety Information for NovoSeven® RT
WARNING: THROMBOSIS
- Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
- Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
- Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis
Warnings and Precautions
- Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
- Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events
- Hypersensitivity reactions, including anaphylaxis, can occur with NovoSeven® RT. Patients with a known hypersensitivity to mouse, hamster, or bovine proteins may be at a higher risk of hypersensitivity reactions. Discontinue infusion and administer appropriate treatment when hypersensitivity reactions occur
- Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed
- Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct correlation to achieving hemostasis
Adverse Reactions
- The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions following the administration of NovoSeven® RT in clinical trials occurred in 4% of patients with acquired hemophilia and 0.2% of bleeding episodes in patients with congenital hemophilia
Drug Interactions
- Thrombosis may occur if NovoSeven® RT is administered concomitantly with Coagulation Factor XIII
Please click here for NovoSeven® RT Prescribing Information, including Boxed Warning.
Indications and Usage
NovoSeven® RT (coagulation Factor VIIa, recombinant) is a coagulation factor indicated for:
- Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
- Treatment of bleeding episodes and perioperative management in adults with acquired hemophilia
References
- NovoSeven RT [package insert]. Plainsboro, NJ: Novo Nordisk Inc.
- National Hemophilia Foundation. MASAC recommendation on administration of inhibitor bypassing agents in the home for patients with hemophilia and inhibitors. (MASAC Document #233.) June 4, 2015. Accessed May 29, 2025. https://www.bleeding.org/sites/default/files/document/files/233homeadministration.pdf
- Mariani G, Herrmann FH, Dolce A, et al; International Factor VII Deficiency Study Group. Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. Thromb Haemost. 2005;93(3):481-487.
- Cleveland Clinic. Factor VII deficiency. Cleveland Clinic. Updated May 15, 2024. Accessed September 30, 2025. https://my.clevelandclinic.org/health/diseases/factor-vii-deficiency
- Amicar. Package insert. Hospira, Inc; 2018.
- Kaseer H, Sanghavi DK. Aminocaproic acid. In: StatPearls. StatPearls Publishing; 2023. Accessed November 7, 2025. https://www.ncbi.nlm.nih.gov/books/NBK554475/
- Cyklokapron. Package insert. Pfizer Inc; 2026.
- Lysteda. Package insert. Ferring Pharmaceuticals Inc; 2020.
- Franchini M, Lippi G. Prothrombin complex concentrates: an update. Blood Transfus. 2010;8(3):149-154.
- Baskaran J, Lopez RA, Cassagnol M. Prothrombin complex concentrate. In: StatPearls. StatPearls Publishing; 2024. Accessed November 7, 2025. https://www.ncbi.nlm.nih.gov/books/NBK539716/
- Kcentra. Package insert. CSL Behring LLC; 2023.
- Balfaxar. Package insert. Octapharma USA Inc; 2023.
- Khawar H, Patel P, Stevens JB, Guzman N. Fresh frozen plasma (FFP). In: StatPearls. StatPearls Publishing; 2025. Accessed November 7, 2025. https://www.ncbi.nlm.nih.gov/books/NBK513347/
- Lethaby A, Wise MR, Weterings MAJ, Bofill Rodriguez M, Brown J. Combined hormonal contraceptives for heavy menstrual bleeding. Cochrane Database Syst Rev. 2019;2(2):CD000154.
- Cleveland Clinic. Birth control pills. Cleveland Clinic. Updated July 5, 2023. Accessed October 7, 2025. https://my.clevelandclinic.org/health/ treatments/3977-birth-control-the-pill
- Cleveland Clinic. RICE method for injury. Cleveland Clinic. Updated January 24, 2025. Accessed November 10, 2025. https://my.clevelandclinic.org/health/treatments/rice-method
- Cleveland Clinic. Nosebleed (epistaxis). Cleveland Clinic. Updated December 18, 2024. Accessed September 30, 2025. https://my.clevelandclinic.org/health/diseases/13464-nosebleed-epistaxis
- Leadon M, Hohman MH. Posterior epistaxis nasal pack. In: StatPearls. StatPearls Publishing; 2023. Accessed November 7, 2025. https://www.ncbi.nlm.nih.gov/books/NBK576436/
- Cleveland Clinic. Electrocauterization. Cleveland Clinic. Updated August 15, 2022. Accessed September 30, 2025. https://my.clevelandclinic.org/health/treatments/24032-electrocauterization
- Smith J, Hanson J, Chowdhury R, Bungard TJ. Community-based management of epistaxis: who bloody knows? Can Pharm J (Ott). 2019;152(3):164-176.
- National Hemophilia Foundation. MASAC recommendations concerning products licensed for the treatment of hemophilia and selected disorders of the coagulation system (MASAC Document #290). October 2, 2024. Accessed July 8, 2026. https://www.bleeding.org/sites/default/files/document/files/MASAC-Products-Licensed.pdf